XXXX -secreting @entity1636 are associated with unique operative risks and outcomes.

@entity1 @entity1369 @entity5 @entity1636 @entity204
BACKGROUND: @entity1636 ( @entity1636 ) that produces @entity1369 is an extremely rare, uncharacterized endocrine @entity5 . Our aim was to characterize this @entity5 in terms of its clinical behavior and @entity1 outcomes. METHODS: A retrospective review was made of all @entity1 who had operative management of @entity1369 -secreting @entity1636 from 1957 to 2000 at the Mayo Clinic. Comparisons were made to @entity1 with non- @entity1369 -secreting @entity1636 treated during the same period. RESULTS: Of 141 @entity1 with @entity1636 , we identified 15 @entity1 with @entity1369 -secreting @entity1636 . Isolated @entity1369 hypersecretion was present in 10 @entity1 , and mixed hormonal secretion was detected in 5. Mean @entity5 size and weight were 10.8 cm and 453 g, respectively. Surgical management included curative resection in 10 @entity1 (67%). Perioperative mortality was 20%. Disease recurred in 7 @entity1 (70%) with a median interval of 17 months. Five-year survival was 52%. @entity1 with @entity1369 -secreting @entity1636 had an increased risk of perioperative mortality (20% vs 5%), yet they had an overall survival of 63 months compared to 19 months for @entity1 with non- @entity1369 -secreting @entity1636 . CONCLUSIONS: @entity1369 hypersecretion occurs in 11% of all ACCs and is associated with unique operative risk and outcome. Although @entity1 harboring @entity1369 -secreting @entity1636 appear to have an increased risk of perioperative @entity204 , survivors may have an improved overall survival rate compared with @entity1 with non- @entity1369 -secreting @entity1636 .
